Stifel Nicolaus analyst Derek Archila reiterated a Buy rating on Momenta Pharmaceuticals on Monday, setting a price target of $47, which is approximately 51.37% above the present share price of $31.05.
Archila expects Momenta Pharmaceuticals to post earnings per share (EPS) of -$0.34 for the second quarter of 2020.
The current consensus among 3 TipRanks analysts is for a Strong Buy rating of shares in Momenta Pharma (NASDAQ:MNTA), with an average price target of $44.
The analysts price targets range from a high of $47 to a low of $40.
In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $8.89 million and a net profit of -$40.67 million. The company's market cap is $3.65 billion.
According to TipRanks.com, Stifel Nicolaus analyst Derek Archila is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 4.2% and a 46.34% success rate.
Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA.